IFM Investors Pty Ltd Grows Position in Johnson & Johnson $JNJ

IFM Investors Pty Ltd grew its stake in Johnson & Johnson (NYSE:JNJ) by 0.7% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 457,246 shares of the company’s stock after purchasing an additional 3,347 shares during the period. Johnson & Johnson comprises approximately 0.8% of IFM Investors Pty Ltd’s investment portfolio, making the stock its 19th largest holding. IFM Investors Pty Ltd’s holdings in Johnson & Johnson were worth $75,830,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of JNJ. Acorns Advisers LLC acquired a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $263,000. Blue Rock Wealth Management LLC raised its stake in shares of Johnson & Johnson by 324.5% during the 1st quarter. Blue Rock Wealth Management LLC now owns 6,486 shares of the company’s stock worth $1,076,000 after buying an additional 4,958 shares during the period. Fortis Capital Advisors LLC raised its stake in shares of Johnson & Johnson by 411.7% during the 1st quarter. Fortis Capital Advisors LLC now owns 14,962 shares of the company’s stock worth $2,481,000 after buying an additional 12,038 shares during the period. Belpointe Asset Management LLC raised its stake in shares of Johnson & Johnson by 35.7% during the 1st quarter. Belpointe Asset Management LLC now owns 32,189 shares of the company’s stock worth $5,338,000 after buying an additional 8,477 shares during the period. Finally, Focus Partners Wealth raised its stake in shares of Johnson & Johnson by 15.4% during the 1st quarter. Focus Partners Wealth now owns 1,193,378 shares of the company’s stock worth $197,910,000 after buying an additional 159,419 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.6%

Shares of JNJ opened at $177.12 on Wednesday. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $181.16. The company has a market capitalization of $426.57 billion, a PE ratio of 18.94, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. The stock has a fifty day simple moving average of $169.51 and a two-hundred day simple moving average of $161.02. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period last year, the company earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 55.61%.

Analysts Set New Price Targets

JNJ has been the subject of several research analyst reports. Citigroup upped their target price on Johnson & Johnson from $185.00 to $200.00 and gave the stock a “buy” rating in a research note on Thursday, August 21st. Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Wall Street Zen downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Friday, September 5th. Leerink Partnrs downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 13th. Finally, Morgan Stanley increased their price objective on Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a research note on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $176.29.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.